On the heels of GW's epilep­sy win, Wall Street dar­ling Zo­genix shares pos­i­tive PhI­II da­ta on ri­val drug

A ri­val is al­ready loom­ing for GW Phar­ma­ceu­ti­cals $GW­PH, the drug­mak­er who scored the very first cannabis-de­rived drug ap­proval on­ly weeks ago to treat rare forms of epilep­sy. Now, Zo­genix is on their heels with pos­i­tive Phase III da­ta for its drug tar­get­ing the same in­di­ca­tion.

In­vestors are re­joic­ing, with Zo­genix’s $ZGNX stock climb­ing near­ly 25% in pre-mar­ket trad­ing. The stock price has al­ready soared 210% in the past 12 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER